Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Jett

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 16, 2000
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancerJ J Weitz, R F Marschke, J A Sloan, et al.
American Journal of Clinical Oncology|October 16, 1999
Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment GroupR J Kirschling, J P Grill, R S Marks, et al.
Annals of Internal Medicine|November 1, 1991
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trialR F Morton, J R Jett, W L McGinnis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1985
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancerJ E Krook, J R Jett, T R Fleming, et al.
American Journal of Clinical Oncology|August 1, 1989
Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancerL K Everson, J R Jett, J R O'Fallon, et al.
Cancer|November 11, 1992
A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinomaM H Veeder, J R Jett, J Q Su, et al.
Cancer|May 1, 1993
A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment GroupD H Gesme, J R Jett, D D Schreffler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1996
Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancerG E Trivers, V M De Benedetti, H L Cawley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinomaJ A Bonner, J A Sloan, T G Shanahan, et al.
Pharmacogenetics|January 26, 1999
p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancerR M Przygodzki, W P Bennett, D G Guinee, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Lung Cancer (Amsterdam, Netherlands)|March 16, 2000
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancerJ J Weitz, R F Marschke, J A Sloan, et al.
American Journal of Clinical Oncology|October 16, 1999
Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment GroupR J Kirschling, J P Grill, R S Marks, et al.
Annals of Internal Medicine|November 1, 1991
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trialR F Morton, J R Jett, W L McGinnis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1985
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancerJ E Krook, J R Jett, T R Fleming, et al.
American Journal of Clinical Oncology|August 1, 1989
Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancerL K Everson, J R Jett, J R O'Fallon, et al.
Cancer|November 11, 1992
A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinomaM H Veeder, J R Jett, J Q Su, et al.
Cancer|May 1, 1993
A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment GroupD H Gesme, J R Jett, D D Schreffler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1996
Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancerG E Trivers, V M De Benedetti, H L Cawley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinomaJ A Bonner, J A Sloan, T G Shanahan, et al.
Pharmacogenetics|January 26, 1999
p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancerR M Przygodzki, W P Bennett, D G Guinee, et al.
Pageof 8